Related Experiment Video
Updated: Mar 3, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
MANAGEMENT OF ENDOCRINE DISEASE: Present and future perspectives for medical therapy of nonfunctioning pituitary
1Institute of Endocrinology, Metabolism and Hypertension, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract:
In contrast to the clear indication for surgical treatment in symptomatic patients with clinically nonfunctioning pituitary adenomas (NFPA), there are no randomized controlled studies comparing therapeutic strategies such as watchful waiting, irradiation or medical therapy for the management of NFPA after surgery. Further, no medical therapy is currently approved for the treatment of NFPA. In this review, we summarize accumulating data on medications currently approved for secreting pituitary adenomas, used off-label in patients with NFPA. Perspectives on overall treatment optimization and potential future therapies are also detailed.
Insights
For nonfunctioning pituitary adenomas (NFPA) after surgery, treatment options like watchful waiting, radiation, or medication lack comparative studies. This review explores off-label medication use for NFPA management.
Area of Science:
- Endocrinology
- Neurosurgery
- Oncology
Background:
- Clinically nonfunctioning pituitary adenomas (NFPA) present treatment challenges post-surgery.
- Evidence comparing watchful waiting, irradiation, and medical therapy for NFPA is limited.
- No specific medical therapies are currently FDA-approved for NFPA treatment.
Purpose of the Study:
- To review current data on medications approved for secreting pituitary adenomas, used off-label for NFPA.
- To discuss treatment optimization strategies for NFPA.
- To explore potential future therapeutic approaches for NFPA.
Main Methods:
- Literature review of studies on pituitary adenoma treatments.
- Analysis of off-label medication use in NFPA management.
- Synthesis of data on approved drugs for secreting adenomas applied to NFPA.
Main Results:
- Accumulating data suggests potential off-label efficacy of certain medications in NFPA.
- Current treatment strategies for post-surgical NFPA lack robust comparative evidence.
- Further research is needed to establish approved medical therapies for NFPA.
Conclusions:
- Off-label use of medications approved for secreting pituitary adenomas warrants further investigation for NFPA.
- Optimizing NFPA management requires exploring novel therapeutic avenues.
- Future research should focus on comparative studies and developing approved NFPA treatments.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Hormones of the Pituitary Gland
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
The Pituitary Gland
Drug Therapy
Antianxiety Medications
Acute Pancreatitis II: Clinical Manifestations and Management

